ArticleHuman vaccines & immunotherapeutics2016
Why we need a vaccine for non-typeable Haemophilus influenzae.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Vaccinations in patients with interstitial lung diseases: a narrative review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Multi-Antigen Protein Vaccine Confers Protection in a Murine Model Against IntranasalVaccines · 2026Article
- Characterization of a conserved outer-membrane protein in non-typeableMicrobiology spectrum · 2026Article
- Genetic organization and mobile-element basis of β-lactam resistance in a polyclonal respiratoryFrontiers in microbiology · 2026Article
- Multi-Component Vaccine Candidates Against Non-TypeableVaccines · 2025Article
- Review
- Article
- Exploiting haem-iron dependence of nontypeableFrontiers in cellular and infection microbiology · 2025Review
- Article
- Heme sequestration by hemophilin frommSphere · 2024Article
- Changing Landscape ofCase reports in infectious diseases · 2024Article
- Can non-typeablePediatric investigation · 2023Article
- Access to highly specialized growth substrates and production of epithelial immunomodulatory metabolites determine survival of Haemophilus influenzae in human airway epithelial cells.PLoS pathogens · 2022Article
- Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use.Clinical microbiology reviews · 2021Review
- Oropharyngeal Carriage ofPathogens (Basel, Switzerland) · 2021Article
- The Role of Non-TypeableFrontiers in cellular and infection microbiology · 2021Review
- Bacterial composition of nasal discharge in children based on highly accurate 16S rRNA gene sequencing analysis.Scientific reports · 2020Article
- Panel 8: Vaccines and immunology.International journal of pediatric otorhinolaryngology · 2020Review
- Article
- Discovery and Contribution of Nontypeable Haemophilus influenzae NTHI1441 to Human Respiratory Epithelial Cell Invasion.Infection and immunity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nontypeable Haemophilus influenzae (NTHi) is increasingly recognized as emerging pathogen. The routine immunization of infants with conjugated vaccines against H. influenzae type b (Hib) has greatly reduced the incidence of invasive Hib disease; however a marked change in the predominant invasive serotype from Hib to NTHi has occurred. Localized infections where the role of H. influenzae is important, such as otitis media in children and acute exacerbations in chronic obstructive pulmonary disease (COPD) in adults, are almost exclusively associated with NTHi isolates. The implementation of pneumococcal conjugate vaccines has resulted in changes in frequency of nasopharynx colonizing pathogens with an increase of NTHi, although this data is yet under debate. An effective vaccine against NTHi is not currently available. The major challenge in developing a successful vaccine is the intrinsic heterogeneity of NTHi. H. influenzae protein D is used as carrier protein in the licensed 10-valent pneumococcal conjugate vaccine (Synflorix, GlaxoSmithKline), but no robust evidences for protective efficacy against NTHi otitis have been until now obtained. Several other vaccine candidates are under investigations and we hope that significant advancements in vaccine development will be achieved in the next future. Genome-based vaccine strategy might provide an additional useful tool for discovering further vaccine antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.